Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.
Ggp is almost a billion market cap without producing gold and MTl is only about 60 million
Market cap producing between 60-80,000 ounce a year with very low cost to produce . There is also significant amount of molybdenum to produce.
Imo, before u invest let the dust settle first and wait for the bottom, it may take days before it it finds its bottom. It is very volatile at the moment. Let the swing traders do their job. Still the fundamentals are still the same.
Initial valuation of the company at £13.50. Hoping for 10-15 next week. The best Aim company so far without thinking of ‘issue of equities’ which is common among Aim companies. No dilution to shareholders that is one big factor for investors.
The problem with antigen using saliva is the sensitivity . It cannot detect asymptomatic patients. It is the same with Abbott. That is why avacta is struggling to validate the test
Imo. Saliva using Pcr is still the gold standard.
If we compare Qiagen’s market cap to its revenue it’s about x5-7. Then applyling it to Novacyt’s conservative revenue of
£300 million x 5-7. My estimate market cap should be at least £1. 5 billion equivalent to at least £20 per share. Dyor
Pmo was taken over very cheaply. The long term debt is a big problem for the company.
Fab is developing therapeutic neutralising antibodies, President Donald Trump was treated with Regeneron’s neutralising antibodies. It is a good sentiment for Covid play companies which are developing therapeutics against Covid 19. Good news for FAB and for investors Patience is always a virtue.
More contracts were already awarded to Novacyt, therefore the forecast for yearend revenue has increased as well. Imo, another additional £150 million to the projected £150 million revenue. Therefore personally my Projected yearend revenue is >£300 million and > £150 million net profit. More than £1 billion market cap is already justified with this figures. Dyor